Frontal Fibrosing Alopecia: Genetics, the Cosmeceutical Question, and What the 2024–2025 Evidence Actually Shows

The first time you see frontal fibrosing alopecia in your chair, you may not even recognize it. The hairline looks off in a way the client cannot quite name. The forehead seems higher than it used to be. The temples have lost their density. The eyebrows have thinned, and small individual hairs have gone missing from the sides. The skin along the new hairline looks smoother and paler than the surrounding scalp, and there is no soft hairline of vellus hairs to be seen. The client has been blaming menopause, or stress, or the years she spent pulling her hair into a tight ponytail, and she is not entirely wrong about any of those things. But what she actually has is a slow-moving, immune-mediated, scarring process that is permanently deleting the follicles at the perimeter of her scalp from front to back.

FFA is the disease of our era. The first case series, published by Steven Kossard in 1994 in the Archives of Dermatology, described six postmenopausal Australian women. By the early 2010s the volume of cases reported globally was rising sharply, and a 2019 multicenter survey of 22 specialist hair clinics across nineteen countries found that cicatricial alopecia accounted for 7.3% of all alopecia diagnoses, with FFA emerging as the single most common type. Whatever is driving this disease, it is doing more of it than it was thirty years ago, and it is now sitting in trichology chairs in numbers that did not exist when most of us were trained.

This is what the peer-reviewed literature actually says about FFA in 2026: what the genetics confirm, what the cosmeceutical hypothesis really shows, what the mechanism looks like at the level of the follicle, and what the data supports for treatment. The story is messier than the headlines suggest, and the clinical implications are different from what most consumer-facing coverage has captured.

What FFA Actually Is

FFA is a primary lymphocytic cicatricial alopecia. Translation: the immune system attacks the upper portion of the hair follicle, the inflammation destroys the follicular stem cell reservoir in the bulge region, and the follicle is replaced by fibrous scar tissue. Once a follicle is gone, it is gone. The disease progresses centimeter by centimeter along the frontal and frontotemporal hairline, frequently spreads to the temples and to the entire perimeter of the scalp over years, and almost always involves the eyebrows. Body hair loss, sideburn loss, and occasional patchy alopecia of the limbs are common. A subset of patients develop facial papules, perifollicular erythema on the forehead, and lichen planus pigmentosus, a related pigmentary disorder of the interfollicular skin.

Histopathologically, FFA is essentially indistinguishable from lichen planopilaris (LPP). The interface dermatitis at the upper follicle, the perifollicular fibrosis, the loss of sebaceous glands, and the eventual replacement of the follicle by a fibrotic tract are identical. For decades the dermatology field debated whether FFA is a clinical variant of LPP or a separate disease. Current consensus is that they share the same pathologic mechanism but represent distinct clinical phenotypes, with FFA occurring in a strikingly specific demographic pattern that LPP does not share.

That demographic pattern is unusual: roughly 95% of cases are female, the great majority are postmenopausal at diagnosis, and the disease was originally described almost exclusively in fair-skinned populations. Over the last decade FFA has been increasingly reported in women of color, in premenopausal women, and rarely in men. The female predominance and the menopause association have driven a hormonal-axis hypothesis from the beginning, but as we will see, that hypothesis has not held up cleanly in the genetic and pharmacologic data.

The Genetics: What the GWAS Confirmed

Tziotzios and colleagues at King’s College London ran the first genome-wide association study in FFA, combining a UK cohort of 844 cases and 3,760 controls with a Spanish replication cohort of 172 cases and 385 controls. They identified four genome-wide significant susceptibility loci on chromosomes 2p22.2, 6p21.1, 8q24.22, and 15q2.1.

Two of the four findings are particularly important for understanding FFA. Within the 6p21.1 locus, fine mapping identified the HLA-B*07:02 allele as the driver, implicating the antigen-presentation system in disease initiation and reinforcing the autoimmune framework that the histology already suggested. Within 2p22.2, the signal pointed to a probable causal missense variant in CYP1B1, the gene encoding cytochrome P450 1B1, an enzyme involved in the metabolism of both endogenous hormones and exogenous xenobiotic compounds. In other words, the same locus is implicated in how the body processes both estrogen metabolites and many environmental chemicals, including some compounds found in cosmetics. Transcriptomic analysis of affected scalp tissue confirmed overrepresentation of innate and adaptive immune-response genes.

What the GWAS established is that FFA is not just an environmental disease and not just a hormonal disease. It is a polygenic, immune-mediated condition with a confirmed inherited component, and the implicated genes happen to sit at the intersection of immune regulation and xenobiotic metabolism. This is the molecular reason the gene-environment story for FFA is more complicated than either side of the cosmetics debate has historically suggested.

The Mechanism: Loss of Immune Privilege at the Bulge

The healthy hair follicle is one of the few sites in the body that maintains constitutive immune privilege. The bulge region, where the follicular stem cells live, downregulates MHC class I expression and produces local immunosuppressive signals so that the stem cell pool is hidden from the adaptive immune system. This is the same biology that makes alopecia areata possible: when immune privilege collapses, autoreactive T cells gain access to follicular antigens and can drive the destruction of the follicle.

In FFA, the data from 2024–2025 reviews converge on the same mechanism. A Th1-skewed CD8+ T-cell response targets the bulge, MHC class I expression upregulates aberrantly on stem cell–adjacent epithelium, and IFN-γ signaling drives destruction of the immune-privileged niche. The downstream cascade involves TGF-β-driven epithelial-mesenchymal transition (EMT), which is the cellular mechanism by which the follicular epithelium is replaced by scarring fibroblasts. PPAR-γ downregulation, observed in FFA biopsies, removes the local lipid-metabolic and anti-inflammatory brake that normally protects the sebaceous gland and the upper follicle. The JAK/STAT pathway is upregulated, which is why JAK inhibitor trials are now in progress.

This is mechanistically distinct from CCCA, which is a fibroproliferative disorder driven in part by PADI3 loss-of-function variants and behaves more like a localized scleroderma-adjacent process. It is mechanistically related to LPP, which shares the same lichenoid interface pattern. And it is mechanistically related to alopecia areata in the sense that both diseases involve immune privilege collapse, although the demographics, location, and reversibility could not be more different. AA targets the bulb and is potentially reversible. FFA targets the bulge and is permanent.

The Cosmeceutical Question

The cosmeceutical hypothesis began with Aldoori in 2016, who found that 48% of FFA patients reported sunscreen use compared with 24% of controls (p < 0.001) and proposed a possible causal role for sunscreen chemicals. Moreno-Arrones in 2019 ran a larger multicenter case-control study of 664 women (335 cases, 329 controls) and found a statistical association between FFA and use of facial sunscreen (OR 1.6) and hormone replacement therapy (OR 1.76) in women, and a much stronger association in the small male cohort (sunscreen OR 11.6, antiaging creams OR 1.84). A 2023 systematic review and meta-analysis in Archives of Dermatological Research found that the facial sunscreen association persisted across pooled data while the moisturizer association did not consistently survive female sub-analysis.

The hypothesis has not gone unchallenged. A 2022 cross-sectional study in Acta Dermato-Venereologica by Porriño-Bustamante and colleagues compared actinic damage in FFA patients versus controls and found that FFA patients had significantly more solar lentigines, actinic keratoses, and sun-induced skin lesions (69.3% vs 50%, p = 0.031). The interpretation: FFA patients may use sunscreen more because they have more cumulative photodamage, not because sunscreen is causing the disease. Reverse causation is a real possibility. A Brazilian study of 451 multiracial women with FFA, in a population with low baseline sunscreen use, found no significant association with sunscreen and instead implicated formaldehyde-based hair-straightening, ordinary facial soap, and nighttime moisturizer use.

Population-based case-control studies are vulnerable to recall bias because women with a stigmatizing scalp disease are highly motivated to identify potential causes and may report exposures more reliably than healthy controls. The studies have not consistently controlled for cumulative UV exposure, occupation, or socioeconomic factors that influence both sunscreen use and dermatologic care-seeking. And the increasing reports of FFA in dark-skinned populations with low traditional sunscreen use further weaken a sunscreen-as-direct-trigger model.

Diagnosis: What to Recognize Before the Hairline Has Receded

The single most actionable insight in FFA is that the disease is well-established before most clients seek help. By the time a woman notices that her hairline has moved back, she has often lost two to three centimeters of frontal scalp and is years into the immune-mediated process. Earlier recognition saves follicles. The signs trichologists should know:

Eyebrow loss. In one large series, eyebrow involvement preceded scalp hairline involvement in roughly 30–40% of cases. A postmenopausal woman with newly thinning eyebrows, particularly the lateral third, who also has any frontal scalp symptom should be evaluated for FFA.

Trichoscopy of the hairline. Loss of vellus hairs along the frontal hairline is the earliest dermatoscopic sign and is often visible before any clinical hairline recession. Perifollicular erythema, perifollicular scale, and absence of follicular ostia in the affected band are characteristic. The skin within the band looks pale, atrophic, and shiny. Compare to the unaffected scalp behind the band: ostia are present, vellus hairs are visible, the surface is normal.

The lonely hair sign. Isolated single terminal hairs persisting in an otherwise smooth, hairless band of forehead skin, well in front of the new hairline. These follicles will eventually be lost as well, but they are a near-pathognomonic visual and a useful talking point with referring physicians.

Facial papules and lichen planus pigmentosus. Small, monomorphic, skin-colored facial papules on the temples and cheeks, sometimes accompanying greyish patches of pigmentation on the lateral face and neck. Both are increasingly recognized as part of the FFA phenotype, particularly in patients with skin of color.

Body hair loss. Sideburns, limb hair, and pubic hair thinning are reported in a significant minority of FFA patients. A patient who reports needing to shave less than she used to, in the context of any scalp or eyebrow change, is giving you diagnostic information.

Biopsy remains the gold standard. A 4 mm punch biopsy taken from an active hairline edge (where follicles are still present but inflamed) shows the characteristic perifollicular lymphocytic infiltrate, interface dermatitis at the upper follicle, perifollicular fibrosis, and loss of sebaceous glands. A biopsy from the smooth atrophic band behind the active edge will show only fibrosis and is not diagnostic. The biopsy site selection matters.

Treatment: What the 2024 RCT Showed

For nearly two decades the treatment of FFA has been guided almost entirely by retrospective case series and consensus opinion. Saber and colleagues published the first head-to-head randomized comparison of two of the most commonly prescribed systemic agents: finasteride and hydroxychloroquine. The trial enrolled FFA patients and compared 12 months of finasteride 2.5–5 mg daily versus hydroxychloroquine 200–400 mg daily, with disease stabilization, hairline recession, and trichoscopic features as endpoints.

The two agents performed comparably. Both produced disease stabilization in the majority of patients. Both were well tolerated. The clinical takeaway is that hydroxychloroquine is a defensible first-line choice in patients in whom finasteride is contraindicated, refused, or poorly tolerated, which represents a meaningful share of postmenopausal women on the basis of cardiovascular comorbidity, breast cancer history, or personal preference. The trial did not establish either agent as superior on hair regrowth, because hair regrowth in FFA is uncommon by the time patients present.

The broader treatment evidence base for FFA, summarized in 2024–2025 reviews, supports a hierarchical approach:

Five-alpha reductase inhibitors. Dutasteride 0.5 mg daily and finasteride 2.5–5 mg daily have the largest retrospective evidence base. A 2020 series of 224 patients on dutasteride showed 62% frontal stabilization at 12 months versus 30% in untreated patients. The mechanism by which 5-ARIs work in FFA is not fully understood, because FFA is not classically androgen-driven; the most likely explanation is anti-inflammatory crosstalk between DHT-suppressed sebaceous activity and follicular immune signaling, or modulation of the local steroid-metabolic environment via CYP1B1-related pathways. 5-ARIs are not standalone curative; they slow progression in the majority of treated patients.

Hydroxychloroquine. 200–400 mg daily, stabilization in roughly 60% of patients in pooled data, with the 2024 RCT confirming non-inferiority to finasteride. Lower androgenic side effect profile, but requires baseline ophthalmologic screening and ongoing monitoring for retinal toxicity at higher doses.

Intralesional triamcinolone. 5–10 mg/mL injected along the active hairline edge every 4–6 weeks. Effective for active inflammation and perifollicular erythema in early disease. Risk of cutaneous atrophy at the hairline if overdone.

Topical clobetasol or topical tacrolimus. Used for active perifollicular inflammation, generally as adjunct to systemic therapy. Topical pimecrolimus is sometimes used for facial papules and lichen planus pigmentosus.

Topical and oral minoxidil. Often added to support residual non-scarred follicles. Does not affect the primary disease process but may improve cosmetic outcomes by maintaining density in the unaffected zones.

JAK inhibitors. Tofacitinib, ruxolitinib, and baricitinib have been tried in case series and small case studies, with mixed results. Randomized trials are now in progress. The mechanistic rationale (JAK1/3 upregulation, IFN-γ signaling) is sound. The clinical data is not yet definitive.

Hair transplantation. Almost universally fails over time in active FFA because the disease attacks transplanted follicles in the same fashion that it attacks native ones. Surgical restoration is generally reserved for patients with documented disease quiescence for several years.

Why FFA Belongs in the Trichology Curriculum

FFA sits at the intersection of every clinical skill that distinguishes a trained trichologist from a stylist with good intentions. It requires reading subtle dermatoscopic signs at a hairline that still looks largely normal. It requires asking about eyebrows and body hair when the client came in for “a receding hairline.” It requires understanding immune privilege and scarring biology well enough to explain to a client why this is permanent and why early treatment matters. It requires the kind of professional partnership with a dermatologist that lets the client get on a 5-ARI or hydroxychloroquine within weeks rather than after a year of being told her hair loss is just menopause.

It also requires honesty. Clients with FFA have often been dismissed for years before they reach a hair specialist. They have been told they were stressed, vain, imagining things, or aging. The act of being seen, being correctly diagnosed, and being given a real treatment plan, even one that does not promise regrowth, is therapeutic in itself. FFA is one of the conditions where the best trichology work happens before the medications start.

And FFA is the disease most likely to make trichologists humble about what we do not yet know. The genetics are confirmed but only partially explanatory. The cosmeceutical association is reproducible but not proven causal. The treatment is empirical and slow. The patients are appearing in larger numbers every year for reasons we cannot fully account for. Anyone who tells you they have FFA figured out is either selling something or has not read the 2024–2025 reviews.